Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHYF) Common Equity (2017 - 2025)

Historic Common Equity for Innate Pharma (IPHYF) over the last 9 years, with Q2 2025 value amounting to $5.8 million.

  • Innate Pharma's Common Equity fell 8122.29% to $5.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.8 million, marking a year-over-year decrease of 8122.29%. This contributed to the annual value of $9.4 million for FY2024, which is 8309.53% down from last year.
  • Per Innate Pharma's latest filing, its Common Equity stood at $5.8 million for Q2 2025, which was down 8122.29% from $9.4 million recorded in Q4 2024.
  • Innate Pharma's 5-year Common Equity high stood at $160.8 million for Q2 2021, and its period low was $5.8 million during Q2 2025.
  • Its 5-year average for Common Equity is $69.8 million, with a median of $55.8 million in 2023.
  • As far as peak fluctuations go, Innate Pharma's Common Equity plummeted by 9992.26% in 2021, and later surged by 107.69% in 2023.
  • Innate Pharma's Common Equity (Quarter) stood at $122.9 million in 2021, then plummeted by 55.05% to $55.2 million in 2022, then grew by 1.08% to $55.8 million in 2023, then plummeted by 83.1% to $9.4 million in 2024, then tumbled by 38.32% to $5.8 million in 2025.
  • Its Common Equity stands at $5.8 million for Q2 2025, versus $9.4 million for Q4 2024 and $31.0 million for Q2 2024.